[Lotus Pharmaceutical] May 2026 Revenue Reached NTD 2.32 Billion (+105.8% YoY)
Lotus Pharmaceutical announced its consolidated revenue for May 2026 reached NTD 2.32 billion (NTD 2,324,237 thousand), a remarkable 105.8% increase compared to the same period last year, demonstrating highly robust global business growth.
📋 Article Processing Timeline
- 📰 Published: May 1, 2026 at 09:00
- 🔍 Collected: June 12, 2026 at 08:00 (1007h 0m after Published)
- 🤖 AI Analyzed: June 12, 2026 at 16:41 (8h 41m after Collected)
Company Code: 1795
Company Name: Lotus Pharmaceutical
Industry Category: Biotechnology and Medical Care
Data Month: May 2026
Monthly Revenue: 2,324,237 thousand NTD (2.32 billion NTD)
YoY Change: +105.8%
Keywords: Monthly Revenue, Biotechnology and Medical Care
Company Name: Lotus Pharmaceutical
Industry Category: Biotechnology and Medical Care
Data Month: May 2026
Monthly Revenue: 2,324,237 thousand NTD (2.32 billion NTD)
YoY Change: +105.8%
Keywords: Monthly Revenue, Biotechnology and Medical Care
FAQ
What was Lotus Pharmaceutical's revenue for May 2026?
Lotus Pharmaceutical recorded a revenue of NTD 2.32 billion (NTD 2,324,237 thousand), which is a 105.8% increase compared to May 2025.
What is the stock code and industry sector for Lotus Pharmaceutical?
The stock code is 1795 on the Taiwan Stock Exchange (TWSE), and it belongs to the Biotechnology and Medical Care sector.
What is driving Lotus Pharmaceutical's significant revenue growth?
The growth is primarily driven by strong export sales of high-barrier generic drugs, particularly oncology treatments, in global markets like the US.